Tumor Necrosis Factor B (TNFB ) genetic variants and its increased expression are associated with vitiligo susceptibility

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Laddha, Naresh C ^a   Dwivedi, Mitesh ^a   Gani, Amina R ^a   Mansuri, Mohmmad Shoab ^a   Begum, Rasheedunnisa ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; LYMPHOTOXIN; MESSENGER RNA; ICAM1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXON; FEMALE; GENDER BIAS; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VITILIGO; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EXONS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOTOXIN-ALPHA; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; VITILIGO; YOUNG ADULT;

EID: 84896729282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081736     Document Type: Article

References (87)

1. Ortonne JP, Bose SK (1993) Vitiligo: Where do we stand? Pigment Cell Res 8: 61-72.
2. Majumder PP, Nordlund JJ, Nath SK (1993) Pattern of familial aggregation of vitiligo. Arch Dermatol 129: 994-998.
3. Nath SK, Majumder PP, Nordlund JJ (1994) Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 55: 981-990.
4. Sun X, Xu A, Wei X, Ouyang J, Lu L, et al. (2006) Genetic epidemiology of vitiligo: a study of 815 probands and their families from south China. Int J Dermatol 45: 1176-1181.
5. Taieb A, Picardo M, VETF Members (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20: 27-35.
6. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16: 208-214.
7. Laberge G, Mailloux CM, Gowan K, Holland P, Bennett DC, et al. (2005) Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res 18: 300-305.
8. Spritz RA (2007) The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res 20: 271-278.
9. Spritz RA (2008) The genetics of generalized vitiligo. Curr Dir Autoimmunity 10: 244-257.
10. Feldmann M, Brennan FM, Maini R (1998) Cytokines in autoimmune disorders. Int Rev Immunol 17: 217-228.
11. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, et al. (2002) New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 15: 87-92.
12. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, et al. (2002) Vitiligo and epidermal microenvironment: possible involvement of keratinocytederived cytokines. Arch. Dermatol 138: 273-274.
13. Smith CA (1994) The TNF receptor super family of cellular and viral proteinsactivation, co stimulation and death. Cell 76: 959-962.
14. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452.
15. Funahashi I, Kawatsu M, Kajikawa T, Takeo K, Asahi T, et al. (1991) Usefulness of glycosylated and recombinant human lymphotoxin for growth inhibition of human and murine solid tumors and experimental metastasis in mice. J Immunother 10: 28-38.
16. Lucas R, Lou J, Morel DR, Ricou B, Suter PM, et al. (1997) TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukocyte Biol 61: 551-558.
17. Beutler B, Bazzoni F (1998). TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis 24: 216-230.
18. Laddha NC, Dwivedi M, Begum R (2012) Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS ONE 7: e52298.
19. Messer G, Spengler U, Jung MC, Honold G, Blomer K, et al. (1991) Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-b gene correlates with a variant amino acid in position 26 and a reduced level of TNF-b production. J Exp Med 173: 209-219.
20. Whichelow CE, Hitman GA, Raafat I, Bottazzo GF, Sachs JA (1996) The effect of TNF*B gene polymorphism on TNF-alpha and -beta secretion level in patients with insulin dependent diabetes mellitus and healthy controls. Eur J Immunogenet 23: 425-435.
21. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, et al. (2002) Functional SNPs in the lymphotoxin alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32: 650-654.
22. Huang CL, Nordlund JJ, Boissy R (2002) Vitiligo: A manifestation of apoptosis. Am J Clin Dermatol 3: 301-308.
23. Yohn JJ, Critelli M, Lyons MB, Norris DA (1990) Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol 90: 233-237.
24. Al Badri AM (1993) Abnormal expression of MHC class ll and ICAM-l by melanocytes in vitiligo. J Pathol 169: 203-206.
25. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
26. Gottenberg JE, Busson M, Loiseau P, Dourche M, Cohen-Solal J, et al. (2004) Association of transforming growth factor-β1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjogren's syndrome. Arthritis Rheum 50: 570-580.
27. Zhang XJ, Chen JJ, Liu JB (2005) The genetic concept of vitiligo. J Dermatol Sci 39: 137-146.
28. Shajil EM, Agrawal D, Vagadia K, Marfatia YS, Begum R (2006) Vitiligo: Clinical profiles in Vadodara, Gujarat. Ind J Dermatol 51: 100-104.
29. Shajil EM, Chatterjee S, Agrawal D, Bagchi T, Begum R (2006) Vitiligo: Pathomechanisms and genetic polymorphism of susceptible genes. Ind J Exp Biol 44: 526-539.
30. Kemp EH, Waterman EA, Weetman AP (2001) Immunological pathomechanisms in vitiligo. Expert Rev Mol Med 23: 1-22.
31. Cui J, Bystryn JC (1995) Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 131: 314-318.
32. Harning R, Cui J, Bystryn JC (1991) Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97: 1078-1080.
33. Kemp EH, Gawkrodger DJ, MacNeil S, Watson PF, Weetman AP (1997) Detection of tyrosinase autoantibodies in patients with vitiligo using 35Slabeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 109: 69-73.
34. Le Gal FA, Avril M, Bosq J, Lefebvre P, Deschemin JC, et al. (2001) Direct evidence to support the role of antigen-specific CD8 (+) T-cells in melanoma-associated vitiligo. J Invest Dermatol 117: 1464-1470.
35. Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, et al. (2003) Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2- positive vitiligo patients. J Invest Dermatol 121: 550-556.
36. Le Poole I, Luiten R (2008) Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 10: 227-243.
37. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18: 175-182.
38. Zeff RA, Freitag A, Grin CM, Grant-Kels JM (1997) The immune response in halo nevi. J Am Acad Dermatol 37: 620-624.
39. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, et al. (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51: 52-61.
40. Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah, et al. (2013) Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 22: 245-250.
41. Kaluza W, Reuss E, Grossmann S, Hug R, Schoopf RE, et al. (2000) Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNFalpha 238A promoter polymorphism. J Invest Dermatol 114: 1180-1183.
42. Wilson A, Symons J, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor-a promoter on transcriptional activation. Proc Natl Acad Sci USA 94: 3195-3199.
43. Gonza'lez S, Rodrigo L, Marti'nez-Borra J, Lo'pez-Va' zquez A, Fuentes D, et al. (2003) TNF-a -308A promoter polymorphism is associated with enhanced TNF-a production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 98: 1101-1106.
44. Dawkins RL, Christiansen FT, Kay PH, Garlepp M, McCluskey J, et al. (1983) Disease associations with complotypes, supratypes and haplotypes. Immunol Rev 70: 1-22.
45. Candore G, Lio D, Colonna Romano G, Caruso C (2002) Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 1: 29-35.
46. Candore G, Modica MA, Lio D, Colonna-Romano G, Listi F, et al. (2003) Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: a genetically determined defect of C4 influences immunological parameters of healthy carriers of the haplotype. Biomed Pharmacother 57: 274-277.
47. Dawkins RL, Spies T, Strominger JL, Hansen JA (1989) Some disease-associated ancestral haplotype carry a polymorphism of TNF. Hum Immunol 26: 91-94.
48. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, et al. (2006). Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci USA 103: 14074-14079.
49. Smerdel-Ramoya A, Finholt C, Lilleby V, Gilboe IM, Harbo HF, et al. (2005) Systemic lupus erythematosus and the extended major histocompatibility complex- evidence for several predisposing loci. Rheumatology (Oxford) 44: 1368-1373.
50. McHugh NJ, Owen P, Cox B, Dunphy J, Welsh K (2006) MHC Class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis 65: 488-494.
51. Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, et al. (2006) Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet 2: e107.
52. Kobayashi Y, Miyomotu D, Asada M, Obinata M, Osawa T (1986) Cloning and expression of human lymphotoxin mRNA derived from a human T cell hydrydoma. J Biochem 100: 727-730.
53. Abraham LJ, Kroeger KM (1999) Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 66: 562-566.
54. Steinman L (1995) Escape from 'horror autotoxicus': pathogenesis and treatment of autoimmune disease. Cell 80: 7-10.
55. Yamada A, Ichihara S, Murase Y, Kato T, Izawa H, et al. (2004) Lack of association of polymorphisms of the lymphotoxin alpha gene with myocardial infarction in Japanese. J Mol Med 82: 477-483.
56. Hamid YH, Urhammer SA, Glqmer C, Borch-Johnsen K, Jørgensen T, et al. (2005) The common T60N polymorphism of the lymphotoxin-alpha gene is associated with type 2 diabetes and other phenotypes of the metabolic syndrome. Diabetologia 48: 445-451.
57. Pociot F, Briant L, Jongeneel CV, Molvig J, Worsaae H, et al. (1993) Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-a and TNF-b by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 23: 224-231.
58. Wajkowicz-Kalijska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, et al. (2003) Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 83: 683-695.
59. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1983) Elevated serum tumor necrosis factor-a levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 24: 663-665.
60. Bettinotti MP, Hartung K, Deicher H, Messer G, Keller E, et al. (1993) Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus: TNFB MHC haplotypes. Immunogenetics 37: 449-454.
61. Kim TG, Kim HY, Lee SH, Cho CS, Park SH, et al. (1996) Systemic lupus erythematosus with nephritis is strongly associated with the TNFB*2 homozygote in the Korean population. Hum Immunol 46: 10-17.
62. Lee SH, Park SH, Min JK, Kim SI, Yoo WH, et al. (1997) Decreased tumour necrosis factor-beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 6: 603-609.
63. Zhang J, Ai R, Chow F (1997) The polymorphisms of HLA-DR and TNF B loci in northern Chinese Han nationality and susceptibility to systemic lupus erythematosus. Chin Med Sci J 12: 107-110.
64. Whitacre CC (2001) Sex differences in autoimmune disease. Nat Immunol 2: 777-780.
65. Panchanathan R, Choubey D (2012) Murine BAFF expression is up-regulated by estrogen and interferons: Implications for sex bias in the development of autoimmunity. Mol Immunol 53: 15-23.
66. Martinez-Esparza M, Jimenez-Cervantes C, Solano F, Lozano JA, Garcia-Borron JC (1998) Mechanisms of melanogenesis inhibition by tumor necrosis factor-α in B16-F10 mouse melanoma cells. Eur J Biochem 255: 139-146.
67. + T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 83: 683-695.
68. + ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 26: 586-591.
69. Hedley SJ, Metcalfe R, Gawkrodger DJ, Weetman AP, Mac Neil S (1998) Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules. Br J Dermatol 139: 965-973.
70. Ahn SK, Choi EH, Lee SH, Won JH, Hann SK, et al. (1994) Immunohisto-chemical studies from vitiligo- comparison between active and inactive lesions. Yonsei Med J 35: 404-410.
71. Morelli JG, Norris DA (1993). Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol 100: 191-195.
72. Reimann E, Kingo K, Karelson M, Reemann P, Loite U, et al. (2012) The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells. Hum Immunol 73: 393-398.
73. Yagi H, Tokura Y, Furukawa F, Takigawa M (1997) Vitiligo with raised inflammatory borders: involvement of T cell immunity and keratinocytes expressing MHC class II and ICAM-1 molecules. Eur J Dermatol Clin 7: 19-22.
74. Singh A, Sharma P, Kar HK, Sharma VK, Tembhre MK, et al. (2012) HLA alleles and amino acid signatures of the peptide binding pockets of HLA molecules in Vitiligo. J Invest Dermatol 132: 124-134.
75. Birlea SA, Ahmad FJ, Uddin RM, Ahmad S, Pal SS, et al. (2013) Association of Generalized Vitiligo with HLA Class II Loci in Patients from the Indian Subcontinent. J Invest Dermatol 133: 1369-1372.
76. Dwivedi M, Laddha NC, Imran M, Shah BJ, Begum R (2011) Cytotoxic Tlymphocyte associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment cell Melanoma Res 24: 737-740.
77. Imran M, Laddha NC, Dwivedi M, Mansuri MS, Singh J, et al. (2012) Interleukin-4 genetic variants correlate with its transcript and protein levels in vitiligo patients. Brit J Dermatol 167: 314-323.
78. Dwivedi M, Laddha NC, Begum R (2013) Correlation of increased MYG1 expression and its promoter polymorphism with disease progression and higher susceptibility in vitiligo patients. J Dermatol Sci 71: 195-202.
79. Dwivedi M, Laddha NC, Shah K, Shah BJ, Begum R (2013) Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in disease onset and progression of generalized vitiligo. J Interferon Cytokine Res. doi:10.1089/jir.2012.0171.
80. Dwivedi M, Laddha NC, Mansuri MS, Marfatia YS, Begum R (2013) Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. Brit J Dermatol. doi: 10.1111/bjd.12467.
81. Shajil EM, Laddha NC, Chatterjee S, Gani AR, Malek RA, et al. (2007) Association of catalase T/C exon 9 and glutathione peroxidase codon 200 polymorphisms in relation to their activities and oxidative stress with vitiligo susceptibility in Gujarat population. Pigment Cell Res 20: 405-407.
82. Dwivedi M, Gupta K, Gulla KC, Laddha NC, Hajela K, et al. (2009) Lack of genetic association of promoter and structural variants of Mannan-binding lectin (MBL2) gene with susceptibility to generalized vitiligo. Brit J Dermatol 161: 63-69.
83. Dwivedi M, Laddha NC, Shajil EM, Shah BJ, Begum R (2008) The ACE gene I/D polymorphism is not associated with generalized Vitiligo Susceptibility in Gujarat population. Pigment Cell Melanoma Res 21: 407-408.
84. Laddha NC, Dwivedi M, Shajil EM, Prajapati H, Marfatia YS, et al. (2008) Association of PTPN22 1858C/T polymorphism with vitiligo susceptibility in Gujarat population. J Dermatol Sci 49: 260-262.
85. Laddha NC, Dwivedi M, Gani AR, Shajil EM, Begum R (2013). Involvement of superoxide dismutase isoenzymes and their genetic variants in progression of and higher susceptibility to vitiligo. Free Radic Biol Med 65: 1110-1125.
86. Wong GH, Goeddel DV (1988) Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242: 941-944.
87. Marklund SL (1992). Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. J Biol Chem 267: 6696-6701.